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However, recanalization is a complex process that involves
thrombus organization, neovascularization, and fibrinoly-
sis.11-13 The underlying mechanisms have been extensively
investigated in animal models of DVT, and events intrin-
sic to the thrombus appear to be quantitatively more
important than systemically activated extrinsic fibrinoly-
sis.12-14 Although examination of the processes that occur
within the thrombus is more difficult in the clinical setting,
several plasma markers of coagulation and fibrinolysis have
been developed that enable investigation of the systemic
milieu in which these events occur. Prothrombin fragment
1+2 (F 1+2), generated in the conversion of prothrombin
to thrombin, reflects activated coagulation, and tissue-type
plasminogen activator (t-PA) and plasminogen activator
inhibitor (PAI-1) activity are markers of fibrinolytic activa-
tion and inhibition, respectively. t-PA antigen includes
both active t-PA and t-PA inhibitor complexes and primar-
ily reflects PAI-1 levels.15,16
The purpose of this study was to evaluate the relation-
ship between markers of activated coagulation, fibrinolytic
activation and inhibition, and the degree to which recanal-
ization occurs.
METHODS
Consecutive patients with a first ultrasound-confirmed
episode of DVT at the University of Washington Medical
Center (Seattle, Wash) were asked to participate in this
prospective natural history study. Patients were excluded
from enrollment if they were unable or unwilling to pro-
vide informed consent, if they had undergone anticoagu-
lant therapy with therapeutic doses before enrollment, if
Natural history studies employing serial venous ultra-
sonography have established that deep venous thrombi
undergo a dynamic evolution soon after formation.
Although recurrent thrombotic events are much more
common than appreciated clinically,1,2 thrombus is cleared
from the deep veins in most patients and the venous lumen
is eventually reestablished.3,4 Most of these changes occur
during the first 3 months after deep venous thrombosis
(DVT), with an approximately 50% reduction in thrombus
load during this time.5 Approximately 55% of subjects will
show complete recanalization within 6 to 9 months of
thrombosis.6,7
Although recurrent thrombosis2,8 and the rate and
extent of recanalization5,9 are important determinants of
long-term outcome, the factors that contribute to these
events remain poorly understood. We have previously
reported increased levels of thrombin activation markers at
the time of presentation to be important predictors of
ultrasound-documented recurrent thrombotic events.10
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Objective: Recanalization is common after acute deep venous thrombosis, but the factors that contribute to its variable
extent are unknown. The purpose of this study was to examine the relationship between recanalization and plasma
markers of coagulation and fibrinolysis.
Methods: Subjects with an ultrasound-confirmed deep venous thrombosis had prothrombin fragment 1+2 (F 1+2), tis-
sue plasminogen activator (t-PA) activity, plasminogen activator inhibitor (PAI-1) activity, and t-PA antigen levels
determined before anticoagulation therapy. Ultrasound and plasma studies were repeated at 14 days, 1 month, and
every 3 months for 1 year.
Results: Among 71 enrolled subjects, F 1+2 levels normalized within 14 days. The mean t-PA activity was within the
normal range at all follow-up intervals. However, the mean t-PA antigen (10.7 ± 10.5 to 13.6 ± 13.5 ng/mL; P = .04)
and PAI-1 (9.0 ± 8.1 to 13.2 ± 17.3 U/mL; P = .05) levels increased between the time of presentation and day 14.
The mean reduction in thrombus score among 44 patients who completed 9 months of follow-up was 60.9% (± 42.1%).
Percent recanalization was directly associated with initial t-PA activity levels (R = .4; P = .006) and inversely related to
F 1+2 (R = –. 5; P = .004), t-PA antigen (R = –.5, P = .002), and PAI-1 (r = –. 5, P = .001) levels. However, only ini-
tial F 1+2 (P = .0009) and t-PA antigen (P = .004) levels were independent predictors of the degree of recanalization.
Conclusion: Although the mechanisms by which the venous lumen is restored are still being elucidated, recanalization
is inversely related to levels of activated coagulation (F 1+2) and fibrinolytic inhibition (t-PA antigen) at the time of
presentation. (J Vasc Surg 2002;35:278-85.)
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there was clinical or ultrasound scan evidence of previous
DVT, or if comorbid medical conditions or residence pre-
cluded return for follow-up visits. The study protocol was
approved by the University of Washington Human
Subjects Committee, and informed consent was obtained
from all subjects.
Immediately after enrollment, a history and physical
examination were performed and a risk factor score was
determined, according to the International Society for
Cardiovascular Surgery, North American Chapter/Society
for Vascular Surgery reporting standards in venous dis-
ease.17 Blood was drawn for determination of plasma 
F 1+2, D dimer crosslinked fibrin degradation products, 
t-PA activity and antigen, and PAI-1 activity levels before
the administration of anticoagulant therapy (day 0).
Treatment was instituted as determined by the patient’s
primary physician after initial plasma samples were
obtained. The patients were requested to return for 
follow-up ultrasound examination of both lower extremi-
ties at intervals of 3, 7, and 14 days and 1, 3, 6, 9, and 12
months after initial presentation. Blood was also drawn for
the determination of plasma markers at 14 days and 1, 3,
6, and 12 months.
Color-flow duplex ultrasound examinations were per-
formed with an Ultramark 9 instrument (Advanced
Technology Laboratories, Bothell, Wash) with the patient
in 15 degrees reverse Trendelenburg’s position. All deep
and superficial venous segments from the inferior vena
cava to the tibial veins were imaged, and venous segments
were classified as patent, partially occluded, or completely
occluded on the basis of standard ultrasound criteria,
which included compressibility and the presence of spon-
taneous or augmented Doppler and color flow.18 DVT
was classified as either proximal, involving segments from
the popliteal vein to the inferior vena cava regardless of
calf vein involvement, or isolated to the calf veins. A
thrombus score was calculated for each limb with a 24-
point scale as described in the updated reporting standards
for venous disease.17
Blood was anticoagulated with the addition of 4.5 mL
whole blood to 0.5 mL of either 500 mmol/L acidified
citrate (t-PA assay) or 105 mmol/L sodium citrate. After
centrifugation for 15 minutes at 2000g, plasma was
removed and frozen at –80°C until analysis. t-PA and PAI-
1 activities were measured with immunofunctional assays
(Chromolize t-PA and PAI-1, Biopool Inc, Umea,
Sweden). t-PA was captured with noninhibitory anti–t-PA
bound to a microtiter plate, and active t-PA measured with
a plasminogen-chromogenic substrate reagent.19 PAI-1
was captured on active t-PA coated plates, and bound PAI-
Fig 1. Boxplot of International Society for Cardiovascular Surgery, North American Chapter/Society for Vascular Surgery
thrombus score during first year after acute deep venous thrombosis. Top, middle, and bottom lines of box represent 75th,
50th (median), and 25th percentiles. Closed square shows mean, with top and bottom error bars representing 90th and 10th
percentiles. Numbers above figure represent number of patients evaluated at each follow-up interval.
Table I Thrombotic risk factors
Risk factor No. of patients
Age ≥ 40 years 52 (73.2%)
Active malignant disease 19 (26.8%)
Immobilization > 3 days 17 (23.9%)
Estrogen therapy 16 (22.5%)
Recent surgery 13 (18.3%)
Family history of venous thromboembolism 9 (12.7%)
Cardiac disease 6 (8.5%)
Inflammatory bowel disease 6 (8.5%)
Recent limb trauma 6 (8.5%)
Documented thrombophilia 5 (7.0%)
Pregnancy 2 (2.8%)
Obesity 2 (2.8%)
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1 assayed with anti-PAI-1 antibody. F 1+2, quantitative D
dimer, and t-PA antigen levels were determined with
enzyme-linked immunoadsorbent assays as previously
described.20,21
Active t-PA, t-PA antigen, and PAI-1 activity levels fol-
low a circadian rhythm with a nadir of t-PA activity and
peaks of t-PA antigen and PAI-1 activity occurring in the
morning.22,23 Because day 0 studies needed to be obtained
before anticoagulation therapy, the timing of the initial
blood draws was more variable than for follow-up studies.
For day 0 studies, 2.9% of the samples were drawn between
12 PM and 7 AM, 47.1% were drawn between 7 AM and 4 PM,
and 50% were drawn between 4 PM and 12 PM. For studies
at other intervals, 1.7% of the samples were drawn between
12 PM and 7 AM, 85.9% were drawn between 7 AM and 4 PM,
and 12.5% were obtained between 4 PM and 12 PM. Normal
daytime ranges for t-PA activity are 0.6 to 2.1 IU/mL
(from 10 AM to 4 PM), for t-PA antigen are 3 to 12 ng/mL
(from 7 AM to 4 PM), and for PAI-1 activity are 1.7 to 11
U/mL (from 10 AM to 4 PM).24 Normal ranges for D dimer
and F 1+2 were considered to be less than 400 ng/mL and
0.4 to 1.1 nmol/L, respectively.
All results are reported as the mean ± the standard
deviation (sd). Differences in individual measures repeated
over time (thrombus score, percent recanalization, and
plasma markers) were evaluated with repeated measures
analysis of variance with orthonormalized difference con-
trasts.25 Degree of recanalization [percent recanalization =
(initial thrombus score – final thrombus score)/initial
thrombus score × 100] was the primary outcome variable
considered. Differences in percent recanalization at 9 to
12 months were compared with Student t test for cate-
goric data and linear regression for continuous variables.
Variables significant at a P value of .10 or less in the bivari-
ate analysis were entered into a multivariate regression
model with percent recanalization. Statistical significance
for all comparisons was defined at a P value of .05 or less.
RESULTS
Between October 1997 and March 2000, 71 patients
were enrolled in this prospective study. Among these, 66
patients (93%) had only leg symptoms, one patient (1.4%)
had symptoms of pulmonary embolism alone, and four
patients (5.6%) were asymptomatic. Subjects included 36
female patients (50.7%) and had a mean age of 51.8 years
(sd ± 16.0 years). The mean International Society for
Cardiovascular Surgery, North American Chapter/Society
for Vascular Surgery risk factor score was 4.0 (± 2.8) with
the distribution of risk factors as shown in Table I.
Thrombosis involved the proximal veins in 44 patients
(62%) and was confined to the calf veins in 27 (38%). The
left limb was involved in 29 patients (40.8%), the right limb
in 31 patients (43.7%), and both limbs in 11 patients
(15.5%). Among the 66 patients followed beyond the first
week, 51 (77.3%) underwent treatment initially with intra-
venous heparin or subcutaneous low molecular weight
heparin followed by warfarin, two (3.0%) underwent treat-
ment only with an initial course of heparin or low molecu-
lar weight heparin, five (7.6%) received only warfarin
therapy, and eight (12.1%) were not initially anticoagulated.
The follow-up period for enrolled patients averaged
367 days (± 247 days). Progressive recanalization was
observed with a reduction in mean thrombus score from
5.1 (range, 1 to 25; sd, ± 4.7) at the time of presentation
to 1.8 (range, 0 to 6; sd, ± 1.9) at 12 months (Fig 1).
Mean percent recanalization was 52.4% (± 41.7%) at 6
months, 57.9% (± 45.4%) at 9 months, and 58.8% (±
44.2%) at 12 months. Differences in percent recanaliza-
tion in individual patients were significantly different
between 6 and 9 months (P = .03) but not between 9 and
12 months (P = .09).
Changes in plasma levels of the coagulation and fibri-
nolytic markers are shown in Table II. As previously
reported in relation to the risk of recurrent thrombosis,10
mean F 1+2 levels decreased and normalized within 14
days of presentation. Quantitative D dimer levels also
decreased, although mean levels remained elevated
beyond the normal range throughout the follow-up
period. Mean t-PA activity levels were within the normal
range at presentation and did not change significantly dur-
ing subsequent study intervals. Mean t-PA antigen levels
were also within the normal range at presentation but rose
above the normal range during the first 14 days. Finally,
plasma PAI-1 activity significantly increased between pre-
sentation and days 14 and 28.
Because no significant recanalization occurred
between 9 and 12 months, percent recanalization at the
last follow-up visit between 9 and 12 months was used in
Table II. Coagulation and fibrinolytic markers (mean ± standard deviation)
F 1+2 D dimer t-PA activity t-PA antigen PAI-1 
Interval (nmol/L) (ng/mL) (U/mL) (ng/mL) (U/mL)
Day 0 2.8 (± 2.2) 6742 (± 13,244) 0.88 (± 0.49) 10.7 (± 10.5) 9.0 (± 8.1)
Day 14 1.1 (± 1.2)* 2599 (± 4563)* 0.89 (± 0.54) 13.6 (± 13.5)* 13.2 (± 17.3)*
1 Month 0.8 (± 0.8)* 1427 (± 3084)* 0.89 (± 0.63) 12.1 (± 8.6) 14.3 (± 21.3)*
3 Months 0.7 (± 0.8)* 2039 (± 10,321)* 0.82 (± 0.49) 10.0 (± 6.3) 10.2 (± 8.9)
6 Months 0.7 (± 0.6)* 914 (± 1719)* 0.90 (± 0.43) 9.0 (± 5.2) 8.9 (± 8.1)
1 Year 0.9 (± 0.7) 1003 (± 1179)* 0.96 (± 0.52) 8.3 (± 4.4) 9.2 (± 12.0)
*Significantly different (P ≤ .05) from average of preceding interval (analysis of variance for repeat measures).
F 1+2, Prothrombin fragment 1+2; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor.
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the analysis of the determinants of recanalization. Mean
percent recanalization among the 44 patients who com-
pleted at least 9 months of follow-up was 60.9% (±
42.1%). Recanalization was greater in female patients than
in male patients (66.3% ± 39.7% versus 55.1% ± 45.0%),
but this difference was not statistically significant (P = .4).
In comparison with proximal thrombosis, a trend toward
greater recanalization was present among patients with
isolated calf vein thrombosis (71.3% ± 39.1% versus 52.3%
± 43.5%; P = .1). There was no relationship between age
(R = –.12; P = .43), initial thrombus score (R = –.01; P =
.93), or risk factor score (R = .009; P = .95) and percent
recanalization at the last follow-up examination.
With the exception of D dimer, plasma markers at the
time of presentation were better correlated with recanal-
ization than were those at the last follow-up visit. None of
the coagulation or fibrinolytic markers measured at 9 to
12 months were significantly correlated with recanaliza-
tion. In contrast, prothrombin F 1+2 levels at presentation
were negatively correlated with recanalization, the levels
being lower among those with greater degrees of recanal-
ization (Fig 2,A). Percent recanalization was positively
correlated with t-PA activity and negatively correlated
with initial PAI-1 activity and t-PA antigen (Fig 2,B-D)
Initial D dimer levels were not correlated with eventual
recanalization (R = –.03; P = .8), although the relation-
ship at the last follow-up visit (R = –.29; P = .06)
approached statistical significance.
Variables entered into the multivariate analysis
included the presence of isolated calf vein thrombosis, ini-
Fig 2. Scatterplot of percent recanalization at last follow-up visit versus prothrombin fragment 1+2 (A), tissue plasminogen
activator (t-PA) activity (B), plasminogen activator inhibitor (PAI-1) activity (C), and t-PA antigen (continues on next page)
A
B
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tial F 1+2, PAI-1, t-PA activity and antigen levels, and D
dimer at the last follow-up visit. Among these, only initial
F 1+2 (P = .0009) and t-PA antigen (P = .004) levels were
independently predictive of percent recanalization.
DISCUSSION
The natural history of DVT is characterized by the
interaction of factors that favor formation of new throm-
bus and events that tend to restore the venous lumen.
New thrombotic events have been observed in up to 52%
of patients followed with ultrasonography2 and are related
to the degree of activated coagulation.10 Recanalization
competes with these events and leads to restoration of the
venous lumen in most patients.3,4,26 However, recanaliza-
tion is a complex process that involves thrombus organi-
zation and neovascularization as well as fibrinolysis, and
the factors that favor complete thrombus resolution in
some patients but not others remain poorly defined.
Although processes that occur within the thrombus
are difficult to assess, the development of stable markers of
activated coagulation and fibrinolysis has made it possible
to evaluate the milieu in which these changes occur. F 1+2
and D dimer reflect thrombin activation and intravascular
fibrin formation and degradation, respectively. Proteolytic
degradation of fibrin is initiated by t-PA, which converts
plasminogen to plasmin, and is inhibited by PAI-1.15
Fig 2. cont. (D) at presentation among patients followed at least 9 months (n = 44). Solid regression lines show correla-
tion between recanalization and initial prothrombin fragment 1+2 (R = –.53; P = .0004), t-PA activity (R = .44; P = .005),
PAI-1 activity (R = –.48; P = .002), and t-PA antigen (R = –.48; P = .002) levels. Patients with negative percent recanal-
ization values had progression of thrombus during follow-up period.
C
D
Because plasminogen expression tends to be stable, fibri-
nolytic activity is regulated primarily by the balance
between plasminogen activators and inhibitors.27 Most t-
PA circulates as a functionally inactive complex with its
inhibitors,16 and measurements of t-PA antigen represent
the total of active and complexed t-PA. Because PAI-1 is
present excess and t-PA/PAI-1 complexes are cleared
more slowly than active t-PA,27 t-PA antigen levels are
more closely related to PAI-1 than to t-PA activity.15,16
Increased t-PA antigen levels have shown better correla-
tion with cardiovascular events, such as myocardial infarc-
tion and recurrent DVT, than have PAI-1 levels.16,28-30
As we have previously reported in relation to recurrent
thrombotic events,10 initial F 1+2 levels are markedly ele-
vated and decrease with the institution of anticoagulation
therapy. In contrast, mean t-PA antigen, PAI-1, and t-PA
activity levels are within the normal range at presentation.
Both PAI-1 and t-PA antigen levels increase within 2 to 4
weeks, while t-PA activity levels remain stable. Although
other investigators have reported an increase in t-PA activ-
ity early after DVT,6 our findings are consistent with the
observation that a molar excess of PAI-1 generally results
in rapid inactivation of t-PA.27 Other investigators have
reported PAI-1 levels after acute DVT to either exceed
those of controls6 or to increase after initial presentation.7
We have evaluated the relationship between these
markers and recanalization and found the degree of acti-
vated coagulation and fibrinolytic inhibition to be inde-
pendent predictors of an early and significant reduction in
thrombus load. As implied by the negative correlation with
F 1+2 levels, ongoing thrombus formation is clearly detri-
mental to recanalization. Furthermore, the reciprocal rela-
tionship between t-PA antigen levels and recanalization
reflects the inhibitory effect of PAI-1. Hypofibrinolysis has
been implicated in the pathophysiology of idiopathic DVT,
familial thromboembolism, recurrent thrombosis, and
postoperative DVT.31 Previous studies, although differing
in details and statistical approaches, support the conclusion
that the fibrinolytic system also has a role in the determi-
nation of long-term outcome. On the basis of an early rise
in t-PA activity levels, Killewich et al6 concluded that
enhanced fibrinolysis was associated with recanalization,
although they were unable to show a difference in t-PA
activity levels among those with partial or complete
recanalization. Other investigators have shown a reciprocal
relationship between initial PAI-1 antigen levels and
recanalization at 6 months.7 As with other cardiovascular
events, this study suggests that t-PA antigen levels are more
predictive of long-term outcome than is PAI-1 activity.
Furthermore, although t-PA activity was correlated with
recanalization in the bivariate analysis results, lack of sig-
nificance in the multivariate results implies that inhibitor
levels primarily determine activator activity. Other investi-
gators have similarly noted active t-PA levels to be highly
dependent on PAI-1 levels.15
A few limitations of this study must also be recog-
nized. This study included only a small number of patients
and may have overlooked other potentially important
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determinants of recanalization, including thrombotic risk
factors, gender, and proximal versus distal location of
thrombus. Management was also dictated by the patient’s
primary physician, and 22.7% of the patients did not
undergo standard anticoagulation therapy. Because this
was not a randomized trial and the number of patients
without standard anticoagulation therapy was small, few
valid conclusions regarding the relationship between these
markers and treatment can be reached. Finally, because an
effort was made to obtain initial (day 0) blood samples
before anticoagulation therapy, some variability in initial
fibrinolytic measurements may have resulted from the
time at which samples were obtained.
In conclusion, the results of this study show that
plasma markers of activated coagulation and impaired fi-
brinolysis are important clinical determinants of recanal-
ization. Furthermore, although we are unable to define
the relative importance of events extrinsic and intrinsic to
the thrombus, the results do imply that the systemic
milieu does have relevance to long-term outcome. Not
only is ongoing thrombus formation as reflected by initial
F 1+2 levels a determinant of outcome, but the extent to
which fibrinolysis is inhibited by PAI-1 is also important.
Although this was not a therapeutic trial, these findings
may have some implications for the modification of long-
term outcome. Ensuring an adequate intensity and dura-
tion of anticoagulation therapy is important in the
prevention of recurrent thrombotic events. Appropriate
lifestyle changes have been shown to decrease PAI-1 levels
after acute DVT, although these changes had little effect
on the rate of recurrent thromboembolism.32 Attempts to
reduce postoperative thrombosis through pharmacologic
stimulation of fibrinolysis with anabolic steroids and phen-
formin hydrochloride have also been unsuccessful.29
Although the effects of such manipulation on recanaliza-
tion have not been evaluated, the observation that PAI-1
levels at 9 to 12 months after presentation were not highly
correlated with recanalization may imply that such an
approach would also have limited utility.
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DISCUSSION
Dr Kevin G. Burnand (London, United Kingdom). We have
just received results back from our urokinase knockout model and
our t-PA knockout model. And what we have shown is that in the
urokinase knockout mice, you get absolutely no resolution at all.
However, in the t-PA knockout mice, you get normal resolution,
given that these are experimental thrombi. So, the obvious ques-
tion is, have you looked at urokinase? Would it be possible for you
to go back and look at urokinase? And could your PAI-1 results
be simply an effect of abnormalities in urokinase within the
thrombus?
Dr Meissner. The answer to that is no, we have not looked at
urokinase (u-PA). But the primary measure, the one that was
most important in this particular study, was t-PA antigen, which
actually measures the total of t-PA plus t-PA complexed, with all
its inhibitors, which includes C1 inhibitor amongst others. Only
60% is actually PAI-1. PAI-1 does inhibit two-chain u-PA but not
inactive single-chain u-PA. So, it is possible that what we are mea-
suring is overall fibrinolytic inhibition and not any particular
effect of t-PA.
Dr Burnand. But would it be possible for you to go back and
look at u-PA in any of your blood samples? Because that would
give us some further information as to whether it was the u-PA
activator rather than the t-PA activator that was making the dif-
ference to outcome.
Dr Meissner. That actually may be possible.
Dr Anthony J. Comerota (Philadelphia, Pa). Along the
lines of Dr. Burnand’s question, I would extend his question
just a step farther. Why not look at overall lytic effect, such as
euglobulin lysis time or lysis reflected by a fibrin plate assay?
When we have looked at this in some situations and measured
PAI-1 and measured t-PA activity and t-PA antigen, the overall
lytic effect that we have observed was much greater than what
was reflected by t-PA activity, t-PA antigen, or PAI-1. And I
think that disconnect is leading some of us to premature con-
clusions about the fibrinolytic potential inherent in our vascu-
lar tree.
Another question is, did your patients have compression and
did you monitor their ambulatory activity? And if so, was that
related to recanalization?
Dr Meissner. With respect to your first question, we consid-
ered measuring euglobulin lysis times but decided that we would
try to dissect the fibrinolytic system more carefully.
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Unfortunately, as you are aware and your question implies,
many of the components of the fibrinolytic system, particularly t-
PA activity and PAI-1 activity, have significant diurnal variation
and are difficult to measure. We think the advantage of t-PA anti-
gen is it has a significantly longer half life than either t-PA or PAI-
1 and more closely reflects steady-state levels. And we do think
that elevated levels of t-PA antigen truly reflect increaseed PAI-1
levels.
t-PA antigen levels in general show very close correlation
with euglobulin lysis times, at least in most of the cardiac litera-
ture. Some of the work done by our laboratory medicine depart-
ment suggest that the two are actually very closely correlated.
And with regard to your second question regarding com-
pression, we do routinely recommend that patients wear com-
pression stockings. We do not monitor that, so I cannot give you
any further information. I suspect our compliance is about the
usual for compression stockings.
Dr Edmund J. Harris, Sr (Stanford, Calif). I wonder if you
have any information about prothrombotic states, specifically the
prothrombin mutant, and if that would explain the elevation of
your F 1+2 fragment in these patients?
Dr Meissner. No, we do not have any information about
underlying hypercoagulability. What we do know from our previ-
ous studies is that virtually 100% of patients who present acutely
with DVT will have dramatically elevated levels of prothrombin
1+2 and that the time course of these levels are very closely
related to adequate treatment. That is, they fall rapidly within the
first 14 days in patients who are appropriately anticoagulated. I
cannot give you any further information about underlying throm-
bophilia in these patients.
Dr G. Patrick Clagett (Dallas, Tex). Several studies have
shown that low molecular weight heparin treatment improves res-
olution of thrombi in this condition. So, my question to you is,
among the patients that were treated with low molecular weight
heparin, did you note that, and was there correlation with the fi-
brinolytic activity and prothrombin F 1+2 parameters?
Dr Meissner. Low molecular weight heparins came into use
fairly soon after the start of this study. So, we considered either
unfractionated or low molecular weight heparin to be adequate
treatment and did not have enough numbers to actually break it
down further, so we categorized them together.
The data from this study as well as our previous ones suggest
that activated coagulation is a very bad thing, both for long-term
outcome as well as for eventual valvular function. The role of low
molecular weight heparins, although not proven, is that they may
more rapidly and consistently reduce thrombin generation.
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